Is It Time to Sell MercadoLibre?
MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…
Buy
66
AMED Quote, Financials, Valuation and Earnings
Last price:
$94.54
Seasonality move
:
8.7%
Day range:
$94.22 - $95.35
52-week range:
$82.15 - $98.95
Dividend yield:
0%
P/E ratio:
34.90x
P/S ratio:
1.32x
P/B ratio:
2.59x
Volume:
367.5K
Avg. volume:
399.5K
1-year change:
2.51%
Market cap:
$3.1B
Revenue:
$2.3B
EPS (TTM):
$2.71
Analysts' Opinion
-
Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 10 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $97.38, Amedisys has an estimated upside of 2.97% from its current price of $94.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $73.00 representing 22.81% downside risk from its current price of $94.57.
Fair Value
-
According to the consensus of 11 analysts, Amedisys has 2.97% upside to fair value with a price target of $97.38 per share.
AMED vs. S&P 500
-
Over the past 5 trading days, Amedisys has overperformed the S&P 500 by 0.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Amedisys does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amedisys has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Amedisys reported revenues of $594.8M.
Earnings Growth
-
Amedisys has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Amedisys reported earnings per share of $1.84.
Enterprise value:
3.2B
EV / Invested capital:
2.00x
Price / LTM sales:
1.32x
EV / EBIT:
18.05x
EV / Revenue:
1.36x
PEG ratio (5yr expected):
0.01x
EV / Free cash flow:
14.80x
Price / Operating cash flow:
14.33x
Enterprise value / EBITDA:
13.45x
Gross Profit (TTM):
$1B
Return On Assets:
4.21%
Net Income Margin (TTM):
3.79%
Return On Equity:
7.55%
Return On Invested Capital:
5.72%
Operating Margin:
10.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.3B | $2.4B | $571.4M | $594.8M | |
| Gross Profit | $963.7M | $999.4M | $1B | $249.9M | $260.7M | |
| Operating Income | $178.9M | $202.3M | $217.4M | $52.3M | $60.1M | |
| EBITDA | $245M | $122.2M | $240.5M | $50.1M | $113.1M | |
| Diluted EPS | $3.44 | -$0.64 | $2.71 | $0.44 | $1.84 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $380.5M | $392.5M | $405.6M | $526.4M | $634M | |
| Total Assets | $1.6B | $1.9B | $1.9B | $2.1B | $2.2B | |
| Current Liabilities | $456.1M | $380.2M | $353.1M | $484.9M | $492M | |
| Total Liabilities | $783.6M | $887.7M | $813.6M | $947.2M | $939.5M | |
| Total Equity | $789.6M | $1B | $1.1B | $1.1B | $1.2B | |
| Total Debt | $241.7M | $441.8M | $400.2M | $393.3M | $370.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $110.6M | $104.7M | $224.5M | -$6.5M | -$3.7M | |
| Cash From Investing | -$32.5M | -$13.9M | -$6.7M | -$3.1M | -$1.4M | |
| Cash From Financing | -$79.9M | -$39.2M | -$53.7M | -$8.6M | -$13.3M | |
| Free Cash Flow | $103M | $90.6M | $218.6M | -$9.4M | -$5.1M | |
AMED
Sector
Market Cap
$3.1B
$33.6M
Price % of 52-Week High
95.57%
45.68%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
2.52%
-38.85%
Beta (5-Year)
0.940
0.633
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$94.07
200-day SMA
Buy
Level
$93.30
Bollinger Bands (100)
Buy
Level
91.66 - 94.18
Chaikin Money Flow
Buy
Level
54.4M
20-day SMA
Buy
Level
$94.40
Relative Strength Index (RSI14)
Buy
Level
54.68
ADX Line
Buy
Level
20.1
Williams %R
Neutral
Level
-36.9928
50-day SMA
Buy
Level
$93.62
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
21.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.7247)
Buy
CA Score
(Annual)
Level (0.3366)
Buy
Beneish M-Score
(Annual)
Level (-2.9435)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-0.9423)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Stock Forecast FAQ
In the current month, AMED has received 0 Buy ratings 10 Hold ratings, and 1 Sell ratings. The AMED average analyst price target in the past 3 months is $97.38.
-
Where Will Amedisys Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amedisys share price will rise to $97.38 per share over the next 12 months.
-
What Do Analysts Say About Amedisys?
Analysts are divided on their view about Amedisys share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Amedisys is a Buy and believe this share price will drop from its current level to $101.00.
-
What Is Amedisys's Price Target?
The price target for Amedisys over the next 1-year time period is forecast to be $97.38 according to 11 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 10 analysts rate the stock a Hold.
-
Is AMED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amedisys is a Hold. 10 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AMED?
You can purchase shares of Amedisys via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amedisys shares.
-
What Is The Amedisys Share Price Today?
Amedisys was last trading at $94.54 per share. This represents the most recent stock quote for Amedisys. Yesterday, Amedisys closed at $94.57 per share.
-
How To Buy Amedisys Stock Online?
In order to purchase Amedisys stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Stock High Risk or High Reward?
EV-making supergiant Tesla, Inc. (NASDAQ:TSLA) is going through a difficult…
Why Did Chase Coleman Buy TSM?
Billionaire Chase Coleman of Tiger Global Management has built a…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
76
SBET alert for Jun 5
SharpLink Gaming [SBET] is down 5.78% over the past day.
Buy
80
GWRE alert for Jun 5
Guidewire Software [GWRE] is up 1.64% over the past day.
Buy
70
ZLAB alert for Jun 5
Zai Lab [ZLAB] is up 1.55% over the past day.
